Business
InvestmentPitch Media Video Discusses Resverlogix' Enrollment and Dosing of Patients in a Phase 2b Clinical Trial at a Site at the University of Alberta Hospital in Edmonton, to evaluate Apabetalone as a Potential Oral Treatment for COVID-19 - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2022) - Resverlogix Corp. (TSX: RVX...
About this update from Resverlogix Corp.
[{"type":"text","content":"InvestmentPitch Media Video Discusses Resverlogix' Enrollment and Dosing of Patients in a Phase 2b Clinical Trial at a Site at the University of Alberta Hospital in Edmonton, to evaluate Apabetalone as a Potential Oral Treatment for COVID-19 - Video Available on Investmentpitch.comVancouver, British Columbia--(Newsfile Corp. - January 19, 2022) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF), a world leader in epigenetics, or gene regulation, has begun enrollment and dosing of patients in a Phase 2b clinical trial at a site at the University of Alberta Hospital in Edmonton, to evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19.InvestmentPitch.com has produced a \"video\" which discusses this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter \"Resverlogix\" in the search box.Cannot view this video? Visit:http://www.investmentpitch.com/video/1_0ha2vjqq/Resverlogix-has-begun-enrollment-and-dosing-of-patients-in-a-Phase-2b-clinical-trial-at-a-site-at-the-University-of-Alberta-Hospital-in-Edmonton-to-evaluate-the-safety-and-efficacy-of-apabetalone-as-a-potential-oral-treatment-for-COVID-19Donald McCaffrey, President & CEO, stated, \"Today is a landmark moment, as patients suffering from COVID-19 are now receiving apabetalone treatment for the first time. Additional Canadian sites in Calgary and Toronto will soon be coming online, as well as four new sites in Brazil that will receive apabetalone supply this week. Due to the emergence of the Omicron variant, and the speed with which it has spread, adaptations to the trial have been made to greatly expedite full enrollment. A positive outcome in this trial will enable us to move quickly to deliver apabetalone to patients in need globally, thus providing critical and affordable help in the fight against the ongoing pandemic.\"Dr. Michael Sweeney, Senior VP, Clinical Development, added, \"In addition to reducing the duration of the disease, the hope is that apabetalone will also potentially be able to protect those infected from the effects of chronic COVID-19 - often referred to as long-COVID - experienced months after the initial illness.\" On March 23, 2020, following a publication in Nature, authored by a consortium of top Universities and Research Institutions, Resverlogix launched a COVID-19 program, conduc...